Karl Madaras-Kelly

Karl Madaras-Kelly

Auto-generated profile, based on publicly available information

Karl Madaras-Kelly

College of Pharmacy, Idaho State University, Meridian, ID, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 August 2016 in Journal of Hospital Medicine
Verified
Journal Article
Closed access
KMKarl J. Madaras‐Kelly
Karl J. Madaras‐Kelly
MBMuriel Burk
Muriel Burk
CCChristina Caplinger
Christina Caplinger
JBJefferson G. Bohan
Jefferson G. Bohan
MNMelinda M. Neuhauser
Melinda M. Neuhauser
FGfor the Pneumonia Duration of Therapy Medication Utilization Evaluation Group
for the Pneumonia Duration of Therapy Medication Utilization Evaluation Group

25 April 2015 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
KMKarl Madaras-Kelly
Karl Madaras-Kelly
MJMakoto Jones
Makoto Jones
RRRichard Remington
Richard Remington
CCChristina Caplinger
Christina Caplinger
BHBenedikt D. Huttner
Benedikt D. Huttner
MSMatthew Samore
Matthew Samore
Comparison of antimicrobial de-escalation rates between healthcare settings is problematic. To objectively and electronically measure de-escalation a method based upon the spectrum of antimicrobial regimens administered (i.e., spectrum score) was developed. A Delphi process was used to develop applicable concepts. Spectrum scores were created for 27 antimicrobials based upon susceptibility for 19 organisms. National VA susceptibility data was used to estimate microbial spectrum. Susceptibility estimates were converted to ordinal scores, and values for organisms with multi-drug resistance potential were weighted more heavily. Organism scores were summed to create antibiotic-specific spectrum scores and extended mathematically to score multi-antimicrobial regimens. Vignettes were created from antimicrobial regimens administered to 300 patients hospitalized with pneumonia. Daily spectrum scores were calculated for each case. Hospitalization day 4 scores were subtracted from day 2 scores (i.e., spectrum score ∆). A positive spectrum score ∆ defined de-escalation. Experts ranked each pneumonia case on a 7-point Likert scale (Likert >4 indicated de-escalation). Spectrum score ∆s were compared to expert review. Findings were used to identify score deficiencies. Next, 40 pairs of cases were modified to include antimicrobial administration routes. Each pair contained almost similar regimens; however, one contained oral (PO) the other only intravenous (IV) antimicrobials on day 4 of therapy. Experts reviewed cases as described. Spectrum score ∆ credits to account for PO conversion were derived from the mean paired differences in Likert Score. De-escalation status was evaluated in 100 vignettes containing antimicrobial route by different experts and compared to the modified method. Initial sensitivity and specificity of the spectrum score ∆ to detect expert classified de-escalation events was 86.3 and 96.0%, respectively. In paired cases, the mean (± SD) Likert score was 5.0 (1.5) and 4.6 (1.5) for PO and IV (P = 0.002), respectively. To improve de-escalation event detection, two credits were added to spectrum score ∆s based upon the percentage of antimicrobials administered PO on day 4. The final method, exhibited sensitivity and specificity to detect expert classified de-escalation events of 96.2 and 93.6%, respectively. The final spectrum score method exhibited excellent agreement with expert judgments of de-escalation events in pneumonia.

17 March 2020 in Infection Control & Hospital Epidemiology
Verified
Journal Article
Closed access
PDF file
HHHayli R. Hruza
Hayli R. Hruza
TVTania Velasquez
Tania Velasquez
KMKarl J. Madaras-Kelly
Karl J. Madaras-Kelly
KFKatherine E. Fleming-Dutra
Katherine E. Fleming-Dutra
MSMatthew H. Samore
Matthew H. Samore
JBJorie M. Butler
Jorie M. Butler
Background: Acute respiratory tract infections (ARIs) are commonly diagnosed and major drivers of antibiotic prescribing. Clinician-focused interventions can reduce unnecessary antibiotic prescribing for ARIs. We elicited clinician feedback to design sustainable interventions to improve ARI management by understanding the mental framework of clinicians surrounding antibiotic prescribing within Veterans’ Health Administration clinics.Methods: We conducted one-on-one interviews with clinicians (n = 20) from clinics targeted for intervention at 5 facilities. The theory of planned behavior guided interview questions. Interviews were audio recorded and transcribed for qualitative analysis. An iterative coding approach identified 6 themes.Results: Emergent themes: (1) barriers to appropriate prescribing are multifactorial and include challenges of behavior change; (2) antibiotic prescribing decisions are perceived as autonomous yet, diagnostic uncertainty and perceptions of patient demand can make prescribing decisions difficult; (3) clinicians perceive variation in peer prescribing practices and influences; (4) clinician-focused interventions are valuable if delivered with sensitivity; (5) communication strategies for educating patients are preferred to a shared decisions process; and (6) team standardization of practice and communication are key to facilitate appropriate prescribing. Clinicians perceived audit-and-feedback with peer comparison, academic detailing, and enhanced patient communication strategies as viable approaches to improving appropriate prescribing.Conclusion: Implementation strategies that enable clinicians to overcome diagnostic uncertainty, perceived patient demand, and improve patient education are desired. Implementation strategies were welcomed, and some were more readily accepted (eg, audit feedback) than others (eg, shared decision making). Implementation strategies should address clinicians’ perceptions of antibiotic prescribing practices and should enhance their patient communication skills.

15 December 2016 in American Journal of Health-System Pharmacy
Verified
Journal Article
Closed access
PDF file
CCChristina Caplinger
Christina Caplinger
KCKendall Crane
Kendall Crane
MWMichelle Wilkin
Michelle Wilkin
JBJefferson Bohan
Jefferson Bohan
RRRichard Remington
Richard Remington
KMKarl Madaras-Kelly
Karl Madaras-Kelly
Purpose A protocol to optimize the duration of antimicrobial therapy (DAT) for uncomplicated pneumonia at hospital discharge was evaluated. Methods This retrospective quasiexperimental study was conducted at Boise Veterans Affairs Medical Center from March 2013 through June 2015. Patients were included in the study if they were diagnosed with pneumonia, were hospitalized for more than 24 hours, received antimicrobial treatment within 48 hours of admission, and survived until hospital discharge. The intervention included development of a pneumonia DAT triage algorithm, a process for assessment of the appropriate DAT by pharmacists, and recommendations to providers to limit excessive discharge DATs prescribed. Interrupted time–series analysis was performed to determine the mean monthly DAT per patient and the 30-day readmission rate. Results Of the 707 patients discharged with a diagnosis of pneumonia, 560 met the criteria for study inclusion (366 in the preimplementation group and 194 in the postimplementation group). Change in slope of monthly mean DAT per patient postimplementation was significantly reduced ( p = 0.03) from the preimplementation slope ( p = 0.95), indicating an association between the intervention and mean DAT per patient. The intervention was not associated with the 30-day readmission rate. The mean ± S.D. DAT decreased from 9.5 ± 2.4 days preimplementation to 8.2 ± 2.9 days postimplementation, primarily due to the reduction of outpatient DAT from 5.2 ± 3.0 days preimplementation to 4.2 ± 3.0 days postimplementation. Conclusion A pharmacy-based triage algorithm helped to reduce excessive DATs for patients with pneumonia at hospital discharge without negatively affecting 30-day readmission rates.

16 June 2021 in JACEP Open
Verified
Journal Article
Open access
PDF file
SRSuzette A. Rovelsky
Suzette A. Rovelsky
RRRichard E. Remington
Richard E. Remington
MNMcKenna Nevers
McKenna Nevers
BPBenjamin Pontefract
Benjamin Pontefract
AHAdam L. Hersh
Adam L. Hersh
KMKarl Madaras‐Kelly
Karl Madaras‐Kelly
Objective To compare the effectiveness of amoxicillin-clavulanate versus amoxicillin for adults diagnosed with acute sinusitis (AS). A secondary objective compared antibiotic effectiveness in patients meeting risk criteria for treatment failure. Methods A retrospective cohort study of adults diagnosed with AS prescribed amoxicillin ± clavulanate within Veterans Affairs emergency departments from 2012–2019 was conducted. The primary outcome was sinusitis-related return visits for amoxicillin versus amoxicillin-clavulanate. Secondary outcomes included 30-day infectious complications, gastrointestinal-related adverse events (AEs), and hospitalizations. Propensity-score matching and logistic regression models adjusted for potential confounders. Results A total of 89,627 AS patient visits were identified: 18,576 prescribed amoxicillin and 71,051 amoxicillin-clavulanate. Most patients were male (75,604; 84.4%) and afebrile (80,624; 91.7%). The propensity score-matched cohort comprised 17,929 amoxicillin and 42,294 amoxicillin-clavulanate patient visits. There was no difference in sinusitis-related return visits between amoxicillin (4.9%) and amoxicillin-clavulanate (5.1%) (adjusted odds ratio [OR], 0.96; 95% confidence interval [CI], 0.88, 1.04; P = 0.317). Infectious complications (amoxicillin [0.3%] vs amoxicillin-clavulanate [0.4%]); (adjusted OR, 0.78; 95% CI, 0.57, 1.07; P = 0.124) and hospitalization (amoxicillin [2.0%] vs amoxicillin-clavulanate [2.4%]); (adjusted OR, 0.92; 95% CI, 0.81, 1.04; P = 0.173) were not different. Gastrointestinal-related AEs were lower with amoxicillin (0.5%) relative to amoxicillin-clavulanate (0.7%); (adjusted OR, 0.67; 95% CI, 0.53, 0.86; P = 0.002). Comorbidity was the only guideline-recommended risk factor that was a significant predictor of infectious complications with respect to treatment (amoxicillin vs amoxicillin-clavulanate, OR, 0.63; 95% CI, 0.40 to 0.94; P = 0.022). Conclusion Amoxicillin demonstrated similar efficacy to amoxicillin-clavulanate for AS with fewer gastrointestinal-related AEs. Amoxicillin is a viable option in adults with AS meeting criteria for antibiotic therapy.

9 September 2024 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
BBBenjamin Brintz
Benjamin Brintz
KMKarl Madaras-Kelly
Karl Madaras-Kelly
MNMcKenna Nevers
McKenna Nevers
KEKelly L. Echevarria
Kelly L. Echevarria
MGMatthew B. Goetz
Matthew B. Goetz
MSMatthew H. Samore
Matthew H. Samore
Objective: Bacterial resistance is known to diminish the effectiveness of antibiotics for treatment of urinary tract infections. Review of recent healthcare and antibiotic exposures, as well as prior culture results is recommended to aid in selection of empirical treatment. However, the optimal approach for assessing these data is unclear. We utilized data from the Veterans Health Administration to evaluate relationships between culture and treatment history and the subsequent probability of antibiotic-resistant bacteria identified in urine cultures to further guide clinicians in understanding these risk factors. Methods: Using the XGBoost algorithm, a retrospective cohort of outpatients with urine culture results and antibiotic prescriptions from 2017 to 2022 was used to develop models for predicting antibiotic resistance for three classes of antibiotics: cephalosporins, fluoroquinolones, and trimethoprim/sulfamethoxazole (TMP/SMX) obtained from urine cultures. Model performance was assessed using Area Under the Receiver Operating Characteristic curve (AUC) and Precision-Recall AUC (PRAUC) Results: There were 392,647 prior urine cultures identified in 214,656 patients. A history of bacterial resistance to the specific treatment was the most important predictor of subsequent resistance for positive cultures, followed by a history of specific antibiotic exposure. The models performed better than previously established risk factors alone, especially for fluoroquinolone resistance, with an AUC of .84 and PRAUC of .70. Notably, the models’ performance improved markedly (AUC = .90, PRAUC = .87) when applied to cultures from patients with a known history of resistance to any of the antibiotic classes. Conclusion: These predictive models demonstrate potential in guiding antibiotic prescription and improving infection management.